Plasma membrane lipid bilayer is druggable: Selective delivery of gemcitabine-squalene nano-medicine to cancer cells.

Autor: Lirussi F; UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France; UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France; Plateforme PACE, Laboratoire de Pharmacologie-Toxicologie, Centre Hospitalo-Universitaire Besançon, F-25000 Besançon, France. Electronic address: frederic.lirussi@u-bourgogne.fr., Pyrshev K; UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France; Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine, 46 Nauky ave, 03028 Kyiv, Ukraine; Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, 6431 Fannin St., Houston, TX 77030, USA; Department of Neurochemistry, Palladin Institute of Biochemistry of the NAS of Ukraine, 9 Leontovycha str., 01601 Kyiv, Ukraine., Yesylevskyy S; Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine, 46 Nauky ave, 03028 Kyiv, Ukraine; Laboratoire Chrono Environnement UMR CNRS 6249, Université de Bourgogne Franche-Comté, 16 route de Gray, 25030 Besançon Cedex, France; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, CZ-166 10, Prague 6, Czech Republic; Receptor.AI Inc, 20-22 Wenlock Road, London N1 7GU, United Kingdom., Rivel T; Laboratoire Chrono Environnement UMR CNRS 6249, Université de Bourgogne Franche-Comté, 16 route de Gray, 25030 Besançon Cedex, France; CEITEC - Central European Institute of Technology, Masaryk University, Kamenice, CZ-62500, Brno, Czech Republic., Lopez T; UMR 1231, Lipides Nutrition Cancer, INSERM, F-21000 Dijon, France; UFR des Sciences de Santé, Université Bourgogne Franche-Comté, F-25000 Besançon, France., Coppens E; Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296, Châtenay-Malabry, France., Mura S; Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296, Châtenay-Malabry, France., Couvreur P; Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296, Châtenay-Malabry, France., Ramseyer C; Laboratoire Chrono Environnement UMR CNRS 6249, Université de Bourgogne Franche-Comté, 16 route de Gray, 25030 Besançon Cedex, France.
Jazyk: angličtina
Zdroj: Biochimica et biophysica acta. Molecular basis of disease [Biochim Biophys Acta Mol Basis Dis] 2023 Feb; Vol. 1869 (2), pp. 166614. Date of Electronic Publication: 2022 Dec 07.
DOI: 10.1016/j.bbadis.2022.166614
Abstrakt: Up to now the lipid bilayers were rarely considered as targets in cancer therapy despite pronounced differences in lipid composition between plasma membranes of benign and malignant cells. In this study we demonstrate that the lipid bilayer of the plasma membrane is druggable and suitable for facilitating selective delivery of amphiphilic gemcitabine-squalene nanomedicines to cancer cells. Data from radioactive assays, fluorescent membrane probes and molecular dynamics simulations provide evidence of selective accumulation of gemcitabine-squalene in the plasma membranes with disrupted lipid asymmetry and its subsequent preferential uptake by malignant cells. This causes pronounced cytotoxicity on cancer cells in comparison to their benign counterparts originating from the same tissue.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: